/ /

  • linkedin
  • Increase Font
  • Sharebar

    Modified Anduze technique improves pterygium surgical outcomes

    Approach maintains low complication, low recurrence rates with change in MMC application

     

    On postoperative day 1, all patients received a silicone punctal plug in the lower punctum to avoid dry eye, and all were on an 8-week tapering dose of a strong topical steroid, during which time IOP was measured at 3 and 6 weeks postoperatively. Follow-up visits included evaluation of the cosmetic appearance of the eye, development of any complications, and signs of pterygium recurrence.

    A total of 112 eyes were studied. The average patient age was 53 years (range, 19 to 78 years). Most (62.5%) patients were men. The patients were followed for an average of 171.4 days (range, 1 to 1,026 days).

    Dr. Trattler reported pterygium recurrences in 2 (1.8%) eyes. Complications occurred in 4 (3.6%) eyes, with pyogenic granuloma the only problem. The granulomas were excised under slit lamp observation. No vision-threatening complications developed. There were no cases of scleral melt. The 2 eyes with early recurrences were treated with topical anti-inflammatory medications—one recurrence developed between 4 and 6 months postoperatively and the second after 1 year postoperatively.

    “The results of this clinical review demonstrated that the Anduze bare scleral approach is an effective surgical technique for pterygium excision,” Dr. Trattler said. “Injection of 0.1mL of MMC directly into the subconjunctival space provides excellent results with minimal risk to the patient.”

     

    William B. Trattler, MD

    E: [email protected]

    Dr. Trattler and colleagues have no financial interest in any aspect of this report.

    William B. Trattler, MD
    Dr. Trattler, a corneal specialist at Miami's Center for Excellence in Eye Care, Miami.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results